Novartis seeks injunction against proposed Zometa generic

12-02-2015

Novartis seeks injunction against proposed Zometa generic

wonderisland / Shutterstock.com

Novartis has sued drug company BPI Labs for alleged patent infringement after it requested permission to market a generic version of Novartis’s bone cancer drug Zometa (zoledronic acid).


Novartis, BPI Labs, Zometa, ANDA, US District Court for the Middle District of Florida, zoledronic acid

LSIPR